Background: Schizophrenia is a chronic disease related to long-lasting and tremendous effects on patient’s health in China, which is generally considered as a huge economic burden not only for patients but also for t...Background: Schizophrenia is a chronic disease related to long-lasting and tremendous effects on patient’s health in China, which is generally considered as a huge economic burden not only for patients but also for their caregivers and the whole society. Therefore, it is necessary to conduct an analysis of cost. Previous cost-of-illness (COI) studies have already provided some useful information on the economic burden that schizophrenia brought to global society, including China. Objectives: This systematic review aims to obtain a comprehensive understanding of the economic burden of schizophrenia in China. Method: A literature review was performed through CNKI, Wanfang, CQVIP, EMBASE and Medline databases to identify COI studies published between 2010-2024. The primary outcome of this review was societal cost per schizophrenia patient by cost component, including direct medical costs, non-medical costs and indirect medical costs. Results: 14 COI studies in schizophrenia were identified, covering 7 municipalities and 8 provinces of China. The annual societal cost per patient ranged from 10,765 CNY in Zhejiang province to 406,382 CNY in Xuancheng city (Anhui province). The ratio of indirect cost ranged from 66.6% to 96.8%. The main cost drivers were the productivity losses. There was an enormous heterogeneity between societal cost estimations that could be interpreted by the difference in economic state and regional healthcare resource allocation. Conclusions: This review highlights the large economic burden of schizophrenia in varied areas in China. Substantial cost variation was observed both nationwide and globally, which may be caused by the varied economic situation and healthcare policy. Limitation of this review was summarized, which may provide a useful guidance for the future COI studies in China.展开更多
Introduction: Malaria in pregnancy (MiP) is a public health issue that poses risks to maternal and fetal health. Although the World Health Organization recommends intermittent preventive treatment with sulfadoxine-pyr...Introduction: Malaria in pregnancy (MiP) is a public health issue that poses risks to maternal and fetal health. Although the World Health Organization recommends intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) to prevent MiP, its uptake remains low among endemic countries. This study evaluated IPTp-SP uptake and factors associated with its use at Bonassama District Hospital (BDH) in the Littoral Region of Cameroon. Methods: A cross-sectional study was conducted at BDH from March to June 2022. Data were collected from antenatal care (ANC) attendees who were over 30 weeks pregnant. Asymptomatic malaria infections were assessed using PfHRP2/pLDH diagnostic testing. Pearson Chi-square and Fisher’s Exact tests evaluated associations, while binary logistic regression assessed predictors of optimal IPTp-SP uptake, with statistical significance set at p Results: Of the 393 participants, 273 (69.5%, 95% CI: 64.7 - 74.0) received optimal IPTp-SP dosing. Predictors of IPTp-SP optimization were level of education, religion, gravida, parity, gestational age at first ANC, number of ANC visits, and maternal knowledge of optimal SP dose. Women who had taken at least three doses of IPTp-SP had fewer P. falciparum infections (aOR = 2.6, 95% CI: 1.65 - 4.14, p 0.05). Conclusion: This study revealed that the optimal uptake of IPTp-SP was below the nationwide 80% coverage target set for 2030. This reinforces the urgency to promote early and frequent ANC visits. Additionally, there is a continuous need for health education highlighting the importance of IPTp-SP uptake and using LLINs as essential strategies to reduce MiP.展开更多
文摘Background: Schizophrenia is a chronic disease related to long-lasting and tremendous effects on patient’s health in China, which is generally considered as a huge economic burden not only for patients but also for their caregivers and the whole society. Therefore, it is necessary to conduct an analysis of cost. Previous cost-of-illness (COI) studies have already provided some useful information on the economic burden that schizophrenia brought to global society, including China. Objectives: This systematic review aims to obtain a comprehensive understanding of the economic burden of schizophrenia in China. Method: A literature review was performed through CNKI, Wanfang, CQVIP, EMBASE and Medline databases to identify COI studies published between 2010-2024. The primary outcome of this review was societal cost per schizophrenia patient by cost component, including direct medical costs, non-medical costs and indirect medical costs. Results: 14 COI studies in schizophrenia were identified, covering 7 municipalities and 8 provinces of China. The annual societal cost per patient ranged from 10,765 CNY in Zhejiang province to 406,382 CNY in Xuancheng city (Anhui province). The ratio of indirect cost ranged from 66.6% to 96.8%. The main cost drivers were the productivity losses. There was an enormous heterogeneity between societal cost estimations that could be interpreted by the difference in economic state and regional healthcare resource allocation. Conclusions: This review highlights the large economic burden of schizophrenia in varied areas in China. Substantial cost variation was observed both nationwide and globally, which may be caused by the varied economic situation and healthcare policy. Limitation of this review was summarized, which may provide a useful guidance for the future COI studies in China.
文摘Introduction: Malaria in pregnancy (MiP) is a public health issue that poses risks to maternal and fetal health. Although the World Health Organization recommends intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) to prevent MiP, its uptake remains low among endemic countries. This study evaluated IPTp-SP uptake and factors associated with its use at Bonassama District Hospital (BDH) in the Littoral Region of Cameroon. Methods: A cross-sectional study was conducted at BDH from March to June 2022. Data were collected from antenatal care (ANC) attendees who were over 30 weeks pregnant. Asymptomatic malaria infections were assessed using PfHRP2/pLDH diagnostic testing. Pearson Chi-square and Fisher’s Exact tests evaluated associations, while binary logistic regression assessed predictors of optimal IPTp-SP uptake, with statistical significance set at p Results: Of the 393 participants, 273 (69.5%, 95% CI: 64.7 - 74.0) received optimal IPTp-SP dosing. Predictors of IPTp-SP optimization were level of education, religion, gravida, parity, gestational age at first ANC, number of ANC visits, and maternal knowledge of optimal SP dose. Women who had taken at least three doses of IPTp-SP had fewer P. falciparum infections (aOR = 2.6, 95% CI: 1.65 - 4.14, p 0.05). Conclusion: This study revealed that the optimal uptake of IPTp-SP was below the nationwide 80% coverage target set for 2030. This reinforces the urgency to promote early and frequent ANC visits. Additionally, there is a continuous need for health education highlighting the importance of IPTp-SP uptake and using LLINs as essential strategies to reduce MiP.
